Day One Biopharmaceuticals, Inc. SEC Filings

Day One Biopharmaceuticals (DAWN) filed its Q3 2025 10‑Q, showing continued commercial ramp of OJEMDA. Total revenue was $39.8 million, driven by product revenue of $38.5 million (vs. $20.1 million in Q3 2024). The company reported a net loss of $19.7 million (vs. net income of $37.0 million last year, which included significant license revenue).

Year to date, revenue totaled $104.5 million with $102.6 million from product sales. Operating expenses were $64.0 million in Q3, including R&D of $31.4 million and SG&A of $28.1 million. Cash and cash equivalents were $43.3 million and short‑term investments $408.3 million, for total assets of $513.8 million and stockholders’ equity of $450.9 million as of September 30, 2025.

Customer concentration remains high: two customers accounted for 98.6% of Q3 net product revenue. The Ipsen out‑licensing continues to be recognized over time, with $1.3 million of license revenue in Q3 and deferred revenue of $2.3 million current and $3.0 million long‑term. Shares outstanding were 102,675,502 as of October 31, 2025.

Day One Biopharmaceuticals (DAWN) filed an 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The company also provided a financial results presentation and an updated corporate presentation, furnished as Exhibits 99.1, 99.2 and 99.3.

The materials are furnished, not filed, and are not incorporated by reference unless specifically stated otherwise. The filing lists DAWN common stock on the Nasdaq Global Select Market, and is signed by Charles N. York II, M.B.A., Chief Operating Officer and Chief Financial Officer.

Day One Biopharmaceuticals, Inc. approved a repricing of outstanding employee and director stock options that had an exercise price of $8.00 or greater, reducing those option exercise prices to the company's closing common-stock price on the Effective Date of September 30, 2025 (the New Exercise Price). The Board and Compensation Committee approved the change after consulting an independent compensation consultant and outside counsel, saying the move is intended to retain and motivate key contributors while avoiding dilution from large new equity grants or significant cash payouts.

Repriced options will remain subject to a retention condition: continued service through the one-year anniversary of the Effective Date or a qualifying Corporate Transaction. If an eligible participant does not satisfy the retention requirement, they must pay the difference between the New Exercise Price and the original exercise price upon exercise, except if termination occurs due to death or Disability as defined in the plan.

Charles N. York II, COO and CFO of Day One Biopharmaceuticals, Inc. (DAWN), reported settlement and sales related to Restricted Stock Units (RSUs). On 08/15/2025 Mr. York was deemed to have acquired RSUs totaling 16,875 units in four separate grants (1,375; 2,250; 6,625; 6,625). These RSUs convert one-for-one into common shares upon settlement for no consideration and vest in quarterly 1/16th installments on Feb 15, May 15, Aug 15 and Nov 15, subject to continued service. Following those acquisitions his reported beneficial ownership increased through successive totals shown up to 282,106 shares.

On 08/18/2025 Mr. York sold 4,106 shares at a weighted average price of $6.7671 as part of block trades executed at prices ranging from $6.65 to $6.87; the sale was made solely to cover tax withholding for the RSU settlements. The filing is signed and dated 08/19/2025 and discloses no other transactions or amendments.

Day One Biopharmaceuticals insider transactions: Adam Dubow, listed as the issuer's General Counsel & Secretary and an officer, had multiple Restricted Stock Units (RSUs) settle on 08/15/2025, resulting in the acquisition of 11,087 shares of common stock through four RSU settlements and increasing his reported beneficial ownership in steps to 59,223 shares before a subsequent sale. On 08/18/2025 Dubow sold 4,365 shares in a block trade at a weighted average price of $6.7671 per share; the filing states the sale was made solely to cover tax liabilities related to the RSU settlements. The filing discloses vesting schedules for the RSUs (initial 25% vesting on 11/15/2023, then quarterly installments or 1/16th per quarter as specified) and confirms RSUs convert to one share each upon settlement for no consideration.

Jeremy Bender, Chief Executive Officer and director of Day One Biopharmaceuticals, Inc. (DAWN), reported vesting settlements of multiple Restricted Stock Units (RSUs) on 08/15/2025 that converted into common shares and a subsequent sale on 08/18/2025. The Form 4 shows acquisitions by settlement: 3,562, 4,750, 11,687 and 11,687 RSUs converting to common stock. On 08/18/2025 the filing reports a sale of 16,058 shares at a weighted average price of $6.7671, disclosed as executed to cover the reporting person's tax liability from RSU settlement. The filing also discloses significant indirect holdings across several trusts, including 1,408,285 shares held in the Bender Revocable Trust.

Lauren Merendino, Chief Commercial Officer of Day One Biopharmaceuticals, Inc. (DAWN), reported receipt and partial sale of company shares tied to vested restricted stock units (RSUs). On 08/15/2025 she was treated as acquiring multiple blocks of common stock through vesting of RSUs (3,162; 3,687; 3,687 shares) and the related derivative entries show those RSUs underlie the same share amounts. Following these transactions her reported beneficial ownership figures adjusted across several lines, and on 08/18/2025 she sold 3,766 shares in a block trade at a weighted average price of $6.7671 to cover taxes on RSU settlement.

The filing notes the RSUs represent one share each upon settlement for no consideration, vesting schedules (initial 1/4 on 08/15/2024 with remaining quarterly vesting, and separate 1/16 quarterly vesting for another award) and that RSU sales were solely to cover tax liabilities. The form was filed by one reporting person via attorney-in-fact.

Day One Biopharmaceuticals (DAWN) filed a Form 144 reporting a proposed sale of 16,058 common shares acquired as restricted stock from the issuer on 08/15/2025. The sale is to be effected through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value reported as $108,666.09 and the issuer's total shares outstanding listed as 102,431,933.

The notice records the approximate sale date as 08/18/2025, states no securities were sold by the reporting person in the past three months, and includes the standard representation that the seller is not aware of undisclosed material adverse information. Payment and acquisition details show the shares were issued and paid on 08/15/2025 and described as not applicable for other payment types.

Day One Biopharmaceuticals, Inc. (DAWN) Schedule 13G/A reports that RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and two individuals, Peter Kolchinsky and Rajeev Shah, each disclose 0.00 shares beneficially owned as of June 30, 2025, representing 0.0% of the company’s common stock. The filing lists the reporting persons' citizenships and principal business address and confirms the reporting status and classifications (IA, PN, HC, IN). The report includes a certification that the securities were not acquired to influence control. A Joint Filing Agreement is incorporated by reference.